NHP Label Requirements in Canada: The Bilingual Rules Most Manufacturers Get Wrong

Every year, a meaningful share of NPN applications that reach the Health Canada review queue stall not because of ingredient safety concerns or missing clinical evidence — but because the label is wrong. And not wrong in obvious ways. Wrong in the specific, nuanced ways that Canada’s Natural Health Products Regulations (NHPR) demand and that manufacturers entering the Canadian market from the US or internationally often haven’t fully internalized.

The bilingual labelling requirement is where we see the most preventable rejections. So let’s walk through what the NHPR actually requires, where manufacturers routinely fall short, and how to build a label package that survives Health Canada scrutiny the first time through.

What the NHPR Actually Mandates on Every NHP Label

Under Part 5 of the Natural Health Products Regulations (SOR/2003-196), a natural health product label must include a defined set of elements before the product can legally be sold in Canada. This isn’t a checklist you can approach with a “close enough” mentality — Health Canada reviewers are looking for exact compliance, and the language of the regulation leaves little room for interpretation.

The mandatory elements under sections 86 through 97 of the NHPR include:

• The product name, which must include both a brand name and the proper name of the product
• The NPN or DIN-HM number, once assigned
• Dosage form (tablet, capsule, liquid, topical, etc.)
• Net quantity expressed in metric units
• Medicinal ingredients, listed by proper name with quantity per dosage unit
• Non-medicinal ingredients
• Recommended use or purpose, worded exactly as approved in the product licence
• Recommended dose, including frequency and route of administration
• Risk information: cautions, warnings, contraindications, and known adverse reactions

Beyond those, the label must carry storage conditions, an expiry date, a lot number, and the name and address of the product licence holder. That’s 12 distinct mandatory elements — each with sub-requirements that aren’t always apparent from a plain reading of the text.

One sub-requirement that catches manufacturers off guard: the recommended use wording must match, verbatim, what’s approved in your product licence. Even minor paraphrasing — “helps maintain” versus “maintains” — can be flagged as a labelling non-compliance during post-market inspection or at the time of a site licence audit. We’ve seen companies reprint entire production runs over a three-word difference that slipped through a last-minute copy edit.

The Bilingual Mandate — More Than Just Translating the Front Panel

Canada’s Official Languages Act and the Consumer Packaging and Labelling Act (CPLA) together create a bilingual labelling obligation that applies to most consumer products sold nationally, and NHPs are no exception. But here’s what many manufacturers misunderstand: the requirement doesn’t mean putting French on the front panel and English on the back. It means every mandatory label element must appear in both official languages — including medicinal ingredient names, dosage instructions, risk information, and storage conditions.

Where a product has both inner and outer packaging, the outer label must carry all bilingual mandatory elements in full. The inner label may reference the outer label for some elements, but Health Canada’s Guidance Document for Industry: Labelling of Natural Health Products is specific about which inner-label elements qualify for abbreviated treatment. Assuming the inner label can omit bilingual content because “it’s all on the box” is a common and citable mistake.

Proper names for medicinal ingredients under the NHPR must come from an accepted nomenclature source — typically the Licensed Natural Health Products Database, the Herbal Medicines Compendium, or a recognized pharmacopoeial monograph such as USP or Ph.Eur. These proper names must appear in both English and French. For some botanical ingredients, the French proper name is a direct translation. For others, there’s an accepted French designation that differs from a literal translation, and using the wrong version is a deficiency that reviewers flag consistently.

One scenario we encounter regularly: a US-based supplement brand enters the Canadian market with a label they’ve localized by running English text through translation software. The French reads grammatically, but the proper names for several botanical ingredients are incorrect — and in some cases, the French dosage unit language doesn’t follow the standard phrasing Health Canada expects. The application gets put on hold, the company loses months in the review queue, and the fix requires a full label redesign and resubmission.

It’s a straightforward problem with an equally straightforward solution. But it requires knowing the proper name requirements going in, not discovering them during review.

Five Labelling Errors That Trigger Health Canada Rejections

After working with dozens of manufacturers through the NPN application and site licence compliance process, certain labelling mistakes come up again and again. These five are the most frequent:

1. Using trade names instead of proper names for medicinal ingredients. The NHPR requires the proper name — a standardized designation from an accepted pharmacopoeial or Health Canada source. “Turmeric extract” isn’t sufficient if the applicable monograph requires “Curcuma longa, rhizome.” This seems pedantic until you understand that the proper name is the key Health Canada uses to assess whether the safety and efficacy evidence in your submission actually covers the ingredient on your label.

2. Failing to declare all non-medicinal ingredients. Manufacturers sometimes omit processing excipients — flow agents, coating materials, capsule shell components — under the assumption they’re too minor to matter. Under section 93 of the NHPR, all non-medicinal ingredients must appear on the label. A missing excipient that’s a known allergen is also a post-market recall risk that sits well beyond the label deficiency citation.

3. Ambiguous or incorrect net quantity declarations. The CPLA requires net quantity in metric units for most NHPs. Products sold by count — 60 capsules, for instance — still require metric declarations where applicable. Labels that state “60 capsules / 500 mg” without clarifying whether the 500 mg refers to per-capsule content or total product weight create ambiguity that reviewers flag. The declaration needs to be unambiguous and unqualified.

4. Bilingual risk information that’s incomplete in one language. This happens more often than it should. The English label carries a caution; the French version, updated separately at some point in the design process, doesn’t. Health Canada reviewers read both columns. A caution that appears in one official language only is a straightforward non-compliance — and if the omitted caution is a contraindication for a vulnerable population, the stakes are higher than a rejected application.

5. Font size violations under the CPLA. The Consumer Packaging and Labelling Regulations set minimum type sizes for principal display panel declarations, and these differ from US FDA requirements. The NPN, net quantity, and certain other mandatory elements have minimum size requirements relative to the principal display panel area. Labels designed to US specifications frequently need dimensional redesign for Canadian compliance — a fact that’s much cheaper to address before going to press than after.

A Pre-Submission Label Review Checklist

Before submitting an NPN application — or before going to print on any NHP label revision — run through this sequence:

Step 1: Verify all 12 mandatory elements are present. Use the NHPR sections 86 through 97 directly, not a third-party summary. Summaries miss sub-requirements.

Step 2: Confirm all proper names are from accepted nomenclature sources. Cross-reference each medicinal ingredient against the Licensed Natural Health Products Database or the relevant compendium. Don’t rely on your ingredient supplier’s documentation for proper name accuracy — supplier specs are written for international markets, not Health Canada submissions.

Step 3: Review both official language versions in parallel, side by side. Don’t proofread English and French independently in separate review cycles. Lay them next to each other and confirm that every mandatory element is complete and compliant in both languages simultaneously. This single practice catches the vast majority of bilingual omission errors.

Step 4: Confirm recommended use wording matches the approved product licence text exactly. If you’re working from a pre-licensed version of the label during the application stage, flag this language as provisional and build a workflow that updates it as soon as the NPN is assigned and the approved wording is confirmed.

Step 5: Check CPLA net quantity and type size requirements independently of the NHPR checklist. These are separate regulatory instruments that operate in parallel. Teams focused exclusively on NHPR compliance often miss CPLA requirements entirely — and Health Canada’s reviewers check both.

Health Canada’s Natural and Non-prescription Health Products Directorate (NNHPD) portal includes a label validation tool that catches a meaningful percentage of formatting issues before submission. It’s not a substitute for a thorough in-house review, but it’s a useful final pass.

The NPN review queue is already averaging 10 months or more for many product categories. A label deficiency that could have been identified in a 2-hour internal review can add another 6 to 12 weeks to that timeline — before accounting for the cost of reprinting production-ready packaging or revising bilingual translation files. Getting the label right at the front end of the process isn’t just good compliance practice. It’s the most direct way to protect your market entry timeline.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Androxa. Learn more about our team

Talk to our team about Health Canada compliance Contact us

Related from our network

• NHP Raw Material Testing and COA Verification for Canadian Submissions — Qalitex Laboratories provides ISO 17025–accredited testing for natural health product ingredients and finished goods destined for Canadian market entry.
• EU Cosmetic and Health Product Labelling Under Regulation 1223/2009 — Care Europe covers multilingual labelling obligations and CPNP notification requirements for brands entering the European market.